Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

Last updated: January 10, 2024
Sponsor: Signos Inc
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes Mellitus, Type 2

Hormone Deficiencies

Metabolic Syndrome

Treatment

Continuous Glucose Monitor Device

Clinical Study ID

NCT05874635
201-2022
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Medical diagnosis of Type 2 Diabetes; determined by review of subject-provided mostrecent Hg A1c.
  • Subject is under current care of a primary care provider or specialist
  • Clearance by medical provider to participate in diet, physical activity, and lifestylechanges
  • 18 years and above
  • Own a smartphone and be willing to install the Signos App to personally receive textmessages or have access to a web-based survey to self-report their weight.
  • Willingness to complete quality of life questionnaires or other in-app surveys.
  • Willingness to use CGM device
  • Able to speak and read English
  • Be a Signos mHealth (mobile/web-based) user

Exclusion

Exclusion Criteria:

  • Medical diagnosis of Type 1 Diabetes
  • Type 2 Diabetes currently using insulin or most recent A1c ≥10%
  • Severe hypoglycemia <54 mg/dl resulting in seizure or unconsciousness, or requiringassistance/EMS/hospitalization - within 3 months prior to enrollment
  • Current medical diagnosis of an eating disorder (such as anorexia nervosa or bulimia)
  • Medical conditions (e.g., such as seizure disorder) requiring a specific medical diet.
  • Inborn error of metabolism such as phenylketonuria (PKU), glycogen storage disease,fructose intolerance, Maple Sugar Urine Disease (MSUD).
  • History of 10 or more soft tissue skin infections (such as cellulitis or abscesses)
  • Intolerable skin reaction from adhesive
  • Currently taking any of the following medications: Clozapine, Hydroxyurea, or any formof insulin.

Study Design

Total Participants: 20000
Treatment Group(s): 1
Primary Treatment: Continuous Glucose Monitor Device
Phase:
Study Start date:
May 11, 2023
Estimated Completion Date:
May 10, 2029

Study Description

The scope of this study is to enroll existing and new Signos non-insulin dependent type 2 diabetes mellitus users in a volunteer study that utilizes a continuous glucose monitor (CGM) and mobile health application [Signos] to optimize general wellness and body weight and composition. This is a no more than minimal risk study.

Connect with a study center

  • Signos

    Palo Alto, California 94306
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.